Motixafortide plus G-CSF to mobilize stem cells in multiple myeloma

A Phase Ⅲ, Randomized, Double-Blinded Study Evaluating the Safety and Efficacy of Combination Treatment of Motixafortide and G-CSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma

This study tests whether adding motixafortide to G‑CSF helps mobilize more hematopoietic stem cells for autologous transplant in Chinese patients with multiple myeloma.

Quick facts

• Phase: PHASE3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years to 78 Years
• Sex: All
• Sponsor: Guangzhou Gloria Biosciences Co., Ltd. (industry)
• Drugs / interventions: Daratumumab, chemotherapy
• Locations: 2 sites (Beijing, Beijing Municipality and 1 other locations)
• Trial ID: NCT06514508 on ClinicalTrials.gov

What this trial studies

This randomized, double-blind, placebo-controlled, multicenter Phase 3 bridging study compares motixafortide plus G‑CSF versus placebo plus G‑CSF for stem cell mobilization in Chinese patients with multiple myeloma. Eligible patients (ages 18–78) who are candidates for autologous hematopoietic stem cell transplantation and in first or second response will be randomized to receive motixafortide or placebo alongside standard G‑CSF, followed by leukapheresis to collect mobilized CD34+ cells. The trial will measure mobilization efficacy, safety, and pharmacokinetic/pharmacodynamic profiles to determine whether motixafortide improves stem cell yield or reduces collection time or procedures. Conducted at multiple centers in China, the study is designed as a bridging trial to support use of motixafortide in the local population.

Who should consider this trial

Good fit: Ideal candidates are Chinese adults (18–78) with active multiple myeloma who are eligible for autologous stem cell transplant, currently in first or second complete/partial response, with ECOG 0–1 and adequate organ function.

Not a fit: Patients who are not transplant candidates, have refractory or rapidly progressive disease, significant organ dysfunction, or contraindications to G‑CSF or CXCR4 antagonists are unlikely to benefit.

Why it matters

Potential benefit: If successful, adding motixafortide could increase stem cell yields and reduce the number of apheresis sessions needed for autologous transplant.

How similar studies have performed: Other CXCR4 antagonists like plerixafor are established for stem cell mobilization, and earlier-phase studies of motixafortide have shown promising mobilization results, so this Phase 3 bridging trial builds on prior positive data.

Eligibility criteria

Inclusion Criteria:

* (Limit: 15,000 characters)

  1. Patients must have a signed study informed consent prior to entering the study.
  2. Patients must be between the ages of 18 and 78 years.
  3. Diagnosis of active multiple myeloma (aMM) as defined by IMWG criteria.
  4. At least one week (7 days) from last induction cycle of combination/multi-agent chemotherapy (e.g. KRD \[carfilzomib, lenalidomide, dexamethasone\] or VRD \[bortezomib, lenalidomide, dexamethasone\]) or from last single agent chemotherapy (e.g. lenalidomide, pomalidomide, bortezomib, dexamethasone, etc) prior to the first dose of G-CSF for mobilization.
  5. Eligible for Autologous Hematopoietic stem cell transplantation according to the Investigator's discretion.
  6. The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
  7. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  8. Adequate organ function at screening.
  9. Female subjects must be of non-childbearing potential or, if of childbearing potential, must have a negative serum pregnancy test at screening and negative serum pregnancy test within 72 hours prior to G-CSF first administration. Women of childbearing potential (WOCBP) and male subjects with WOCBP partners must agree to use highly effective contraception method during the study period and within 90 days after the last study treatment.

Exclusion Criteria:

1. Previous history of autologous or allogeneic-HCT.
2. Failed previous HSC collections or collection attempts.
3. Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:

   1. Dexamethasone: 7 days
   2. Thalidomide: 7 days
   3. Lenalidomide: 7 days
   4. Pamolidomide: 7 days
   5. Bortezomib: 7 days
   6. Carfilzomib: 7 days
   7. G-CSF: 14 days
   8. GM-CSF or Neulasta®: 21 days
   9. Erythropoietin or erythrocyte stimulating agents: 30 days
   10. Eltrombopag, romiplostim or platelet stimulating agents: 30 days
   11. Carmustine (BCNU): 42 days/6 weeks
   12. Daratumumab or any other anti-CD38: 28 days
   13. Ixazomib: 7 day.
4. Received \>6 cycles lifetime exposure to thalidomide or lenalidomide.
5. Received \>8 cycles of alkylating agent combinations.
6. Received \> 6 cycles of melphalan.
7. Received prior treatment with radioimmunotherapy (e.g. radionuclides).
8. Received prior treatment with venetoclax.
9. Plans to receive maintenance treatment within 60 days post- transplantation (e.g.lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.).
10. Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
11. Known active CNS metastases or carcinomatous meningitis.
12. A history of allergic reactions attributed to compounds of similar chemical or biologic composition to motixafortide, G-CSF, or other agents used in the study.
13. Has an active or uncontrolled infection requiring systemic therapy.
14. Has a known additional malignancy that is progressing or requires active treatment.
15. Is currently participating and/or receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
16. O2 saturation \< 92% (on room air).
17. Personal history or family history of Long QT Syndrome or Torsade de Pointes.
18. History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
19. Myocardial infarction, CABG, coronary or cerebral artery stenting and/or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months, Angina Pectoris Class \>2 or NYHA Heart Failure Class \>2.
20. ECG at screening showing QTcF \> 470 msec and/or PR \> 280 msec.
21. Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
22. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
23. Is pregnant or breast feeding or expecting to conceive or women of childbearing potential unless consent to use two contraceptive methods or highly effective contraception, within the projected duration of the trial, starting with the Screening Visit through 90 days after the last dose of study drug.
24. Known human immunodeficiency virus (HIV) or active Hepatitis B (e.g., Hepatitis B Surface Antigen \[HBsAg\] reactive and HBV DNA\>500 IU/mL or \>2500 copies/mL) or Hepatitis C (e.g., Hepatitis C Virus \[HCV\] RNA \[qualitative\] is positive).
25. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.

Where this trial is running

Beijing, Beijing Municipality and 1 other locations

• Peking University People's Hospital — Beijing, Beijing Municipality, China (RECRUITING)
• Harbin The First Hospital — Harbin, Hei Longjiang, China (NOT_YET_RECRUITING)

Study contacts

• Study coordinator: Xiaojun Huang, M.D.

Conditions: Multiple Myeloma